PTCT

60.99

2.21% 1.32

Dopo l'orario di chiusura: 60.99

Ptc Therapeutics Inc (PTCT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$59.67

Aprire:

$61.08

Volume 24 ore:

1.00M

Relative Volume:

0.91

Capitalizzazione di mercato:

$5.09B

Reddito:

$1.73B

Utile/perdita netta:

$682.64M

Rapporto P/E:

7.8835

EPS:

7.7364

Flusso di cassa netto:

$411.18M

1 W Prestazione:

-2.51%

1M Prestazione:

-7.10%

6M Prestazione:

-17.10%

1 anno Prestazione:

-10.98%

Intervallo 1D:

$59.88

$62.31

Intervallo di 1 settimana:

$58.80

$65.03

Portata 52W:

$58.80

$90.87

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Nome

Ptc Therapeutics Inc

Settore

Healthcare (1051)

Industria

Biotechnology (593)

Telefono

(908) 222-7000

Indirizzo

500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ

Dipendente

991

Cinguettio

@PTCBio

Prossima data di guadagno

2026-11-03

Ultimi documenti SEC

PTCT's Discussions on Twitter

Compare PTCT vs VRTX, MRNA, REGN, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PTCT Ptc Therapeutics Inc	60.99	5.09B	1.73B	682.64M	411.18M	7.7364
VRTX Vertex Pharmaceuticals Inc	508.75	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.34	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.27	53.22B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.08	42.32B	5.76B	514.49M	1.10B	4.4813

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-09-14	Ripresa	Leerink Partners	Outperform
2026-06-09	Aggiornamento	Citigroup	Neutral → Buy
2026-05-27	Aggiornamento	Jefferies	Hold → Buy
2026-05-08	Aggiornamento	TD Cowen	Hold → Buy
2026-04-10	Iniziato	Raymond James	Outperform
2026-01-28	Ripresa	Barclays	Overweight
2025-12-01	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-06-17	Iniziato	Truist	Buy
2025-05-09	Aggiornamento	BofA Securities	Neutral → Buy
2025-05-07	Aggiornamento	Citigroup	Sell → Neutral
2025-03-11	Aggiornamento	BofA Securities	Underperform → Neutral
2025-03-07	Iniziato	Scotiabank	Sector Perform
2024-12-13	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-12-03	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2024-10-10	Ripresa	Raymond James	Mkt Perform
2024-09-04	Iniziato	Robert W. Baird	Outperform
2024-08-26	Ripresa	UBS	Buy
2024-05-20	Aggiornamento	Raymond James	Underperform → Mkt Perform
2023-12-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-10-30	Aggiornamento	Oppenheimer	Perform → Outperform
2023-10-27	Downgrade	Citigroup	Neutral → Sell
2023-10-06	Downgrade	Truist	Buy → Hold
2023-09-18	Downgrade	Citigroup	Buy → Neutral
2023-09-15	Downgrade	Raymond James	Outperform → Underperform
2023-03-17	Iniziato	SVB Securities	Market Perform
2022-12-14	Iniziato	Goldman	Sell
2022-09-12	Iniziato	Jefferies	Buy
2022-09-09	Iniziato	Morgan Stanley	Equal-Weight
2022-09-01	Iniziato	Citigroup	Buy
2022-04-04	Ripresa	Cantor Fitzgerald	Overweight
2021-10-18	Downgrade	BofA Securities	Neutral → Underperform
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-03-29	Aggiornamento	RBC Capital Mkts	Underperform → Sector Perform
2021-02-12	Downgrade	BofA Securities	Buy → Neutral
2021-01-05	Aggiornamento	Citigroup	Neutral → Buy
2020-11-30	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
2020-10-30	Downgrade	Citigroup	Buy → Neutral
2020-10-28	Iniziato	UBS	Neutral
2020-10-07	Aggiornamento	JP Morgan	Neutral → Overweight
2020-08-25	Iniziato	Raymond James	Outperform
2020-04-09	Aggiornamento	Citigroup	Neutral → Buy
2020-02-20	Downgrade	Citigroup	Buy → Neutral
2020-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2019-11-12	Iniziato	SunTrust	Buy
2019-05-13	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-04-11	Iniziato	Bernstein	Outperform
2018-10-03	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-07-19	Iniziato	Credit Suisse	Outperform
2018-06-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2018-04-04	Downgrade	Barclays	Equal Weight → Underweight
2018-01-29	Ripresa	RBC Capital Mkts	Sector Perform
2017-11-16	Aggiornamento	JP Morgan	Underweight → Neutral
2017-10-26	Downgrade	BofA/Merrill	Neutral → Underperform
2017-10-09	Downgrade	JP Morgan	Neutral → Underweight

Mostra tutto

Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie

Oct 13, 2026

Form 4 PTC Therapeutics Inc: Mark Elliott Boulding (EXEC. VP AND CLO) For: 9 October - Investing.com Canada

Oct 13, 2026

PTC Therapeutics CLO Mark Boulding sells $12,337 in stock - Investing.com

Oct 13, 2026

PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 192 Shares of Company Stock - MarketBeat

Oct 13, 2026

After exercising options at $39.42, PTC Therapeutics (PTCT) CLO Boulding sells 192 shares. - Stock Titan

Oct 13, 2026

PTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month LowTime to Sell? - MarketBeat

Oct 13, 2026

Ptc Therapeutics stock hits 52-week low at $61.20 - Investing.com

Oct 13, 2026